Profit before payment of interest, taxes and amortization: sanofi.com (SNY)

Graphic logo of sanofi.com (SNY)

The French behemoth Sanofi (SNY) relies on high-demand vaccines and treatments for chronic pathologies, while the success of Dupixent guarantees a highly reliable cash flow. EBITDA_Co monitoring confirms this resilience, where 22376.67 represents the current metric value. An impeccable image as a classic manufacturer and a positive business restructuring maintain a high level of trust from the global medical community.

Sanofi (SNY) - Operating profit EBITDA from 11/23/2025 to 11/11/2026

Sanofi S.A. (SNY) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Sanofi Group|SNY - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Sanofi|SNY - Enterprise Value
- business book valuation details:
Equity per Share Sanofi|SNY - Book Capitalization|Market Capitalization to Book Value sanofi.com|SNY - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Sanofi|SNY - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Sanofi SA|SNY - Company Debts|Debts to Net Assets Sanofi|SNY - Company Long-Term Debts|Company Short-Term Debts Sanofi|Immediate Liquidity Ratio sanofi.com
- earnings and valuation multiples indicators:
SNY - Company Net Income|Expected Net Profit Sanofi|SNY - P/E Multiple|Price to Expected Earnings Ratio sanofi.com|SNY - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Sanofi|SNY - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Sanofi|SNY - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months sanofi.com|SNY - Net earnings per share growth this year|Expected net earnings per share growth next year Sanofi
Analysis of all company metrics:SNY Sanofi Group
Flagship merchandise of Sanofi S.A.

This metric measures the actual cash flow from core operations before deducting depreciation and interest. It reflects the business's ability to generate liquidity to cover operating expenses amid inflation. Analyzing actual EBITDA allows for the identification of hidden margin compression resulting from rising costs. For Sanofi (SNY), this metric confirms the defensive qualities of the business. Stable revenue from immunology drugs ensures capital resilience during the company's restructuring.

Who Sanofi competes with

Eli Lilly and Co. (LLY) - Profit before interest, taxes and amortization|ABBV - Profit before payment of interest, taxes and amortization|AZN: Profit before payment of interest, taxes and amortization|NVS: Operating profit EBITDA|Operating profit before amortization MRK|NVO (Novo Nordisk Inc.) - Operating profit EBITDA|Amgen Inc (AMGN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Pfizer Inc. (PFE)|bms.com - Operating profit before amortization|Operating profit EBITDA GSK (GlaxoSmithKline)|Operating profit before depreciation charges Takeda Pharmaceutical Company|TEVA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Dr. Reddy's Labs RDY|VTRS: Operating profit EBITDA|roivant.com (ROIV) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Zai Lab|Operating profit before amortization BHC (Bausch Health Companies Inc.)|Profit before payment of interest, taxes and amortization Cosmos Holdings (COSM)